Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Bipolar I Disorder
Interventions: Inhaled Placebo, Inhaled loxapine 5 mg, Inhaled loxapine 10 mg; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 6
States / cities: Escondido, California • Garden Grove, California • Atlanta, Georgia + 3 more

Conditions: Opioid Dependence, Chronic Pain
Interventions: Enhanced Opioid Stewardship Program; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Cardiovascular Diseases, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases, Coronary Artery Disease
Interventions: CT(Computed Tomography) guided Percutaneous Coronary Intervention, IVUS (Intravascular Ultrasound) guided Percutaneous Coronary Intervention; Device
Lead sponsor: Fundación EPIC; Other
Eligibility: 18 Years to 85 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Jersey City, New Jersey + 1 more

Conditions: Cerebral Palsy, GERD
Interventions: Baclofen, placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 3 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: HNC042 single dose, Placebo single dose, HNC042 multiple ascending doses, Placebo multiple ascending doses; Drug
Lead sponsor: Guangzhou Henovcom Bioscience Co. Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pain Management, Opioid Use, Prostate Cancer
Interventions: Oxycodone, Acetaminophen, Ketamine, Ketorolac; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Infection, Pregnancy
Interventions: Placebo, Probiotic dietary supplement; Drug · Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 251 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: Aptos, California • Santa Cruz, California • Stanford, California

Conditions: Acquired Immunodeficiency Syndrome
Interventions: Couples HIV counseling and testing, Women's relationship-focused HIV counseling and testing; Behavioral
Lead sponsor: National Development and Research Institutes, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Minimally Invasive Surgery, Hysterectomy, Postoperative, Satisfaction
Interventions: postoperative follow up appointment; Other
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, Placebo; Drug · Other
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 26
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 22 more

Conditions: Crohn's Disease
Interventions: Rifaximin EIR, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 78
States / cities: Huntsville, Alabama • Tucson, Arizona • Sherwood, Arkansas + 68 more

Conditions: Infertility
Interventions: INVOcell device, Traditional IVF; Device · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 37 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Carvedilol Controlled Release (CR), lisinopril; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Mild Cognitive Impairment
Interventions: CRT, CBT, Modifiable lifestyle factors, Usual care Psychoeducation; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Knee Osteoarthritis
Interventions: celecoxib; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 45 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Kidney Disease
Interventions: BAY3283142, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 24
States / cities: Huntsville, Alabama • Chula Vista, California • San Dimas, California + 20 more

Conditions: Mandibular Fractures
Interventions: Implants; Procedure
Lead sponsor: AO Clinical Investigation and Publishing Documentation; Other
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: New York, New York • San Antonio, Texas

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: NNC 0070-0002-0453, '2-0453, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Atherosclerosis
Interventions: SB 480848, tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Cypress, California • Normal, Illinois • North Dartmouth, Massachusetts + 1 more

Conditions: Irritable Bowel Syndrome, Abdominal Pain
Interventions: Social Learning and Cognitive Behavioral Therapy (SLCBT), Attention Education Control; Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 36
States / cities: Little Rock, Arkansas • Sacramento, California • Whittier, California + 31 more

Conditions: Alcohol-related Disorders, Alcohol Drinking, Alcoholism, Alcohol Abuse
Interventions: Naltrexone, Modified Behavioral Self-Control Psychotherapy, Brief Behavioral Compliance Enhancement Therapy; Drug · Behavioral
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Radiculopathy
Interventions: Lenalidomide (CC-5013); Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 23
States / cities: Phoenix, Arizona • Tucson, Arizona • Loma Linda, California + 20 more

Conditions: Uterine Septum, Surgical Complication, Septum; Uterus, Treatment Side Effects, Treatment
Interventions: Removal of uterine septum with hysteroscopic scissors without electrosurgery., Hysteroscopic septoplasty utilizing bipolar electrosurgery; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 22 Years to 44 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Staccato Loxapine in Agitated Patients With Bipolar Disorder

Feasibility and Preliminary Efficacy of an Opioid Stewardship Program in Hospitalized Patients With Chronic Pain

A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)

Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy

A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy

HIV Prevention Intervention for Couples

Patient Satisfaction With Postoperative Follow up After Minimally Invasive Hysterectomy

A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

Comparing Intra-vaginal Culture of Embryos to In-vitro Culture of Embryos With Minimal Stimulation

Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.

Comprehensive Cognitive and Affective Intervention for Mild Cognitive Impairment (MCI) for Foreign-Born Arab Americans

Efficacy of Celecoxib vs Placebo to Prevent Pain in a Paced Walk

A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

A Multicenter RCT to Investigate the Treatment of Double (Bilateral) Mandibular Fractures

A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers

A Study To Determine The Effect Of SB-480848 On Asthma

Online Social Learning Program for Parents With Irritable Bowel Syndrome: Raising Resilient Children

A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus

Medication and Counseling for Controlled Drinking (Project SMART)

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy

Surgical Approach to Uterine Septum